Pharmacytimes: Condition Center: Hepatitis C http://www.pharmacytimes.com/condition-resources/hepatitisc/condition-rss Hepatitis C en-us Sun, 30 Apr 2017 01:10:37 UTC Sun, 30 Apr 2017 01:10:37 UTC FDA Approves 2 Hepatitis C Drugs for Use in Pediatric Patients http://www.pharmacytimes.com/product-news/fda-approves-2-hepatitis-c-drugs-for-use-in-pediatric-patients The FDA approved supplemental applications for Sovaldi (sofosubuvir) and Harvoni (ledipasvir and sofosbuvir), marketed by Gilead Sciences Inc., to treat hepatitis C virus (HCV) in pediatric patients.&nbsp; 11:37 AM, Fri April 7, 2017 Hepatitis C Regimen Can Cause Cataracts http://www.pharmacytimes.com/contributor/daniel-holland-pharmd/2017/04/hepatitis-c-regimen-can-cause-cataracts An adverse effect with interferon-ribavirin Hepatitis C therapy that does not stop after discontinuation. 2:03 AM, Mon April 3, 2017 Will Hepatitis C Virus Medication Costs Drop in the Years Ahead? http://www.pharmacytimes.com/resource-centers/hepatitisc/will-hepatitis-c-virus-medicaton-costs-drop-in-the-years-ahead Proposals such as allowing Medicare price negotiation, capping out-of-pocket drug costs, importing drugs, and limiting manufacturer&rsquo; spending on patient marketing could all result in lower HCV drug costs. 5:17 PM, Wed February 8, 2017 Investigational Hepatitis C Drug Granted Priority Review http://www.pharmacytimes.com/product-news/investigational-hepatitis-c-drug-granted-priority-review &nbsp;<br /> The FDA has accepted AbbVie&rsquo;s New Drug Application (NDA) for and granted priority review to its investigational, pan-genotype regimen of glecaprevir/pibrentasvir (G/P).&nbsp; 2:22 PM, Fri February 3, 2017 ISMP Report Questions Safety of Hepatitis C Drugs http://www.pharmacytimes.com/news/ismp-report-questions-safety-of-hepatitis-c-drugs A recently-published Institute for Safe Medication Practices (ISMP) report details updated concerns about newer drugs used to treat hepatitis C virus (HCV).&nbsp; 11:44 AM, Fri January 27, 2017 Epclusa for Hep C: What Pharmacists Should Know http://www.pharmacytimes.com/contributor/timothy-o-shea/2017/01/epclusa-for-hep-c-what-pharmacists-should-know This fixed-dose combination of sofosbuvir and velpatasvir is indicated to treat chronic HCV genotypes 1-6. 9:38 PM, Wed January 4, 2017 Studies in Virology Every Pharmacist Should Know http://www.pharmacytimes.com/contributor/timothy-o-shea/2016/12/studies-in-virology-every-pharmacist-should-know Over the years, a number of landmark clinical studies in virology have been published, shaping how we treat the disease today. 10:35 PM, Tue December 27, 2016 These Treatments Improve PHT in Patients With HIV and HCV http://www.pharmacytimes.com/resource-centers/hiv/these-treatments-improve-pht-in-patients-with-hiv-and-hcv Patients who have human immunodeficiency virus (HIV) infection are at elevated risk for HCV. 3:04 PM, Tue December 13, 2016 Declining Hepatitis C Sales http://www.pharmacytimes.com/contributor/jason-poquette/2016/11/declining-hepatitis-c-sales-failure-or-success Reports show that sales and revenue from Hepatitis C treatments are declining. What does this mean for patients? 10:28 PM, Wed November 16, 2016 Pharmacist Charged for Hepatitis C Drug Fraud http://www.pharmacytimes.com/news/pharmacist-charged-for-hepatitis-c-drug-fraud A former Clinical Pharmacy Manager at a Walgreens specialty pharmacy pleaded guilty to health care fraud crimes committed between October 2014 and April 2016. 8:00 AM, Thu October 27, 2016 5 Highlights from the Pharmacy World This Week http://www.pharmacytimes.com/contributor/charles-ng-pharmd-mba-candidate-2017/2016/10/5-highlights-from-the-pharmacy-world-this-week In case you missed it, here’s the hottest news in pharmacy this week: 11:13 PM, Thu October 6, 2016 Trouble on the Horizon for Gilead's HCV Market Hold http://www.pharmacytimes.com/contributor/austin-hewlett-pharmd-mba-candidate/2016/09/trouble-on-the-horizon-for-gileads-hcv-market-hold Gilead Sciences—maker of hepatitis C virus blockbusters Sovaldi, Harvoni, and, most recently, Epclusa—has come under increasing scrutiny for declining revenues, both in the near-term and beyond. 3:05 AM, Fri September 2, 2016 Managing Drug Interactions in HIV/HCV-Coinfected Patients http://www.pharmacytimes.com/contributor/timothy-o-shea/2016/08/managing-drug-interactions-in-hiv-hcv-coinfected-patients Patients taking mediations for both HIV and HCV must be closely monitored for drug-drug interactions. 3:19 AM, Tue August 23, 2016 Zepatier for Hep C: What Pharmacists Should Know http://www.pharmacytimes.com/contributor/timothy-o-shea/2016/08/zepatier-for-hep-c-what-pharmacists-should-know This fixed-dose combination of elbasvir and grazoprevir is indicated to treat chronic HCV genotypes 1 or 4 with or without ribavirin in adults. 10:38 PM, Sun August 14, 2016 FDA Approves Hep C Treatment for All Major Genotypes http://www.pharmacytimes.com/news/fda-approves-hep-c-treatment-for-all-major-genotypes The FDA today approved Gilead Sciences’ sofosbuvir and velpatasvir (Epclusa) for the treatment of adult patients with chronic hepatitis C virus both with and without cirrhosis. 4:25 AM, Tue June 28, 2016 New Indications Approved for Harvoni http://www.pharmacytimes.com/product-news/new-indications-approved-for-harvoni The FDA has approved Gilead Sciences’ supplemental new drug applications for ledipasvir/sofosbuvir (Harvoni), which can treat chronic hepatitis C patients with advanced liver disease. 7:00 AM, Fri February 19, 2016 Zepatier Approved as Hep C Treatment http://www.pharmacytimes.com/product-news/zepatier-approved-as-hep-c-treatment The FDA has approved Merck’s elbasvir and grazoprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotypes 1 and 4 infections. 7:00 AM, Tue February 2, 2016 HIV Coinfection Doesn't Affect Hep C Treatment Adherence http://www.pharmacytimes.com/resource-centers/hiv/hiv-coinfection-doesnt-affect-hep-c-treatment-adherence One-third of HIV-infected Americans are co-infected with hepatitis C virus (HCV), and 75% to 90% of HIV-positive intravenous drug users are co-infected. 11:59 PM, Wed January 20, 2016 Hep C Treatment for All Genotypes Granted Priority Review http://www.pharmacytimes.com/product-news/hep-c-treatment-for-all-genotypes-granted-priority-review The FDA has given priority review status to a new drug application for Gilead Sciences’ sofosbuvir and velpatasvir as a treatment for chronic genotype 1-6 hepatitis C virus infection. 9:00 PM, Tue January 5, 2016 Once-Daily Viekira Pak Under FDA Review http://www.pharmacytimes.com/product-news/once-daily-viekira-pak-under-fda-review The FDA is taking into consideration a once-daily formulation of AbbVie's ombitasvir, paritaprevir, and ritonavir tablets co-packaged with dasabuvir tablets (Viekira Pak). 7:00 AM, Wed December 9, 2015